Two researchers in a laboratory review a tablet beside a microscope.

Ask Our Experts

Emerging Lung Cancer Treatments: The Next Generation of Precision Care

References

  1. Lung Cancer Statistics | How Common Is Lung Cancer? https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html.
  2. Research, C. for D. E. and. Oncology (Cancer)/Hematologic Malignancies Approval Notifications. FDA https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications (2026).
  3. Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer. American Association for Cancer Research (AACR) https://www.aacr.org/about-the-aacr/newsroom/news-releases/investigational-krason-inhibitor-zoldonrasib-showed-effective-and-durable-responses-in-patients-with-advanced-g12d-mutated-lung-cancer/.
  4. Research, C. for D. E. and. FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma. FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma (2026).
  5. Arbour, K. C. et al. Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer. N. Engl. J. Med. 395, 882–893 (2026).
  6. Zipalertinib Plus Chemotherapy Significantly Extends Progression-Free Survival in First-Line EGFR Exon 20 Insertion-Positive NSCLC. IASLC https://www.iaslc.org/iaslc-news/press-release/zipalertinib-plus-chemotherapy-significantly-extends-progression-free.
  7. Phase 3 DESTINY-Lung04 Trial Shows First-Line Trastuzumab Deruxtecan Significantly Improves Progression-Free Survival in HER2-Mutant NSCLC. IASLC https://www.iaslc.org/iaslc-news/press-release/phase-3-destiny-lung04-trial-shows-first-line-trastuzumab-deruxtecan.
  8. Zidesamtinib Demonstrates 94% Response Rate in TKI-Naive Patients With Advanced ROS1-Positive NSCLC. IASLC https://www.iaslc.org/iaslc-news/press-release/zidesamtinib-demonstrates-94-response-rate-tki-naive-patients-advanced.
  9. Shaw, A. T. et al. Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study. Ann. Oncol. 37, 1242–1252 (2026).
  10. Late-Breaking HARMONi-2 Analysis Shows Ivonescimab Significantly Improves Overall Survival Versus Pembrolizumab in PD-L1-Positive Advanced NSCLC. IASLC https://www.iaslc.org/iaslc-news/press-release/late-breaking-harmoni-2-analysis-shows-ivonescimab-significantly-improves.
  11. Research, C. for D. E. and. FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer. FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer (2025).
  12. IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER. Amgen https://www.amgen.com/newsroom/press-releases/2026/09/imdelltra-in-combination-with-imfinzi-demonstrated-landmark-improvement-in-overall-survival-in-first-line-extensive-stage-small-cell-lung-cancer.
  13. Phase III TAISHAN-302 Trial Shows Tam-Peli Significantly Improves Survival in Relapsed Small-Cell Lung Cancer. IASLC https://www.iaslc.org/iaslc-news/press-release/phase-iii-taishan-302-trial-shows-tam-peli-significantly-improves-survival.
  14. Phase III ARTEMIS-008 Trial Shows Risvutatug Rezetecan Significantly Improves Overall Survival in Relapsed Small-Cell Lung Cancer. IASLC https://www.iaslc.org/iaslc-news/press-release/phase-iii-artemis-008-trial-shows-risvutatug-rezetecan-significantly.

DISCLAIMER
This report and all other information and guidance provided by Private Health Management are not to be used or relied on for any diagnostic or treatment purposes. This report and all other information and guidance are not intended to substitute for individualized medical advice, diagnosis or treatment by a physician who is aware of an individual’s medical history and has had an opportunity to conduct an examination. Do not rely on this report in place of seeking professional medical advice.

Pages: 1 2
See More New Stories
Amy Gallagher

Amy Gallagher, DNP, FNP-C

Associate Clinical Director | Nurse Practitioner

Amy Gallagher is an Associate Clinical Director at Private Health Management with nearly a decade of experience as a nurse practitioner in outpatient hematology and oncology. She is dedicated to supporting patients through complex treatment journeys with clinical expertise and compassionate care. Amy began her career as a registered nurse in an inpatient facility before transitioning to outpatient oncology, where she was recognized with the Nursing Care of Excellence award. She earned her Bachelor of Science in Nursing and Doctor of Nursing Practice from Florida State University.
Gareth Morrison

Gareth J. Morrison, PhD

Vice President, Client Solutions

Gareth J. Morrison is a Senior Research Director at Private Health Management with more than 15 years of experience in academic and translational research, including the past decade dedicated to advancing cancer research. He specializes in lung, gastrointestinal, and genitourinary malignancies and applies his expertise in precision medicine to support individualized treatment strategies for clients. Before joining PHM, Gareth served as a Specialized Research Advisor at USC Norris Comprehensive Cancer Center, where he established and managed an NCI-designated Liquid Biopsy Core to advance method development and biomarker discovery. At Roswell Park Cancer Institute, he was part of the team that launched the Center for Personalized Medicine, where he developed tumor genomic assays and validated a next-generation sequencing test approved by the New York State Clinical Laboratory Evaluation Program. Gareth earned his PhD in Chemical Biology and a Bachelor of Science in Biochemistry from the University of Edinburgh, UK, and a Master of Science in Regulatory Management from the University of Southern California.
Julie Nowicki

Julie Nowicki, PhD

Science Communications Specialist

Julie is a Science Communications Specialist at Private Health Management, where she collaborates with the Research and Clinical teams to translate complex scientific concepts into clear, accessible information for clients and their families. Her work helps bridge the gap between cutting-edge research and personalized patient care. A scientific and medical writer by training, Julie has developed content for both clinical and patient audiences across a range of therapeutic areas, including oncology, hematology, dermatology, and women’s health. Before joining PHM, she served as a Senior Medical Writer, where she created clinical manuscripts, abstracts, congress materials, and educational resources for pharmaceutical clients. Julie earned her PhD in Cell, Molecular, and Developmental Biology from the University of North Carolina at Chapel Hill.